Postlicensure Safety Surveillance for 7-Valent Pneumococcal Conjugate Vaccine

Wise, Robert P.; Iskander, John; Pratt, R. Douglas; Campbell, Scott; Ball, Robert; Pless, Robert P.; Braun, M. Miles
October 2004
JAMA: Journal of the American Medical Association;10/13/2004, Vol. 292 Issue 14, p1702
Academic Journal
Context Clinical trials evaluate a vaccine’s safety before approval, but some risks may escape detection or adequate characterization until larger population exposures occur after licensure. Objective To summarize reports of events occurring after vaccination with 7-valent pneumococcal conjugate vaccine (PCV), including those that may warrant further investigation to assess possible causation by PCV. Design Descriptive epidemiology of reports submitted to the Vaccine Adverse Event Reporting System (VAERS), a national passive surveillance database. Setting and Patients United States during first 2 years after licensure of PCV (February 2000 through February 2002). Reports studied were for children younger than 18 years and vaccinated with PCV. Main Outcome Measures Numbers and proportional distributions of reports. Results A total of 4154 reports of events following PCV were submitted to VAERS, for a rate of 13.2 reports per 100 000 doses distributed. Multiple vaccines were given in 74.3% of reports.The most frequently reported symptoms and signs included fever, injection site reactions, fussiness, rashes, and urticaria. Serious events were described in 14.6% of reports. There were 117 deaths, 23 reports of positive rechallenges, and 34 cases of invasive pneumococcal infections possibly representing vaccine failure. Immune-mediated events occurred in 31.3% of reports. All 14 patients with anaphylactic or anaphylactoid reactions survived. Thrombocytopenia developed in 14 patients and serum sickness in 6 others. Neurologic symptoms occurred in 38% of reports. Seizures described in 393 reports included 94 febrile seizures. Conclusions The majority of reports to VAERS in the first 2 years after licensure of PCV described generally minor adverse events previously identified in clinical trials. The proportion of reports portraying serious events was similar to that for other vaccines. Although there are important limitations in passive surveillance data, and caution in their interpretation is necessary, symptoms experienced by a few children more than once after successive PCV doses, including allergic reactions, prolonged or abnormal crying, fussiness, dyspnea, and gastrointestinal distress, warrant continued surveillance, as do reports of rare but potentially serious events, such as seizures, anaphylactic or anaphylactoid reactions, serum sickness, and thrombocytopenia.


Related Articles

  • Insights into Long-Lasting Protection Induced by RTS,S/ AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children. Guinovart, Caterina; Aponte, John J.; Sacarlal, Jahit; Aide, Pedro; Leach, Amanda; Bassat, Quique; Macete, Eusébio; Dobaño, Carlota; Lievens, Marc; Loucq, Christian; Ballou, W. Ripley; Cohen, Joe; Alonso, Pedro L. // PLoS ONE;2009, Vol. 4 Issue 4, p1 

    Background: The pre-erythrocytic malaria vaccine RTS,S/AS02A has shown to confer protection against clinical malaria for at least 21 months in a trial in Mozambican children. Efficacy varied between different endpoints, such as parasitaemia or clinical malaria; however the underlying mechanisms...

  • What are the Current Advances Regarding HIV Vaccines and HIV Vaccine Trials? Dhalla, Shayesta // Journal of Bioanalysis & Biomedicine;2012, Vol. 4 Issue 3, p1 

    The author discusses the current advances on HIV vaccines around the world. She offers her views on the unsuccessful STEP study, a clinical trial which tested the efficacy of an HIV vaccine. The STEP study was stopped in 2007, which revealed an increase in HIV infection for the first 18 months...

  • Vaccine formulation and delivery device.  // WHO Technical Report Series;2004, Issue 927, p52 

    The article presents the section of the World Health Organization guidelines on nonclinical evaluation of vaccines concerning vaccine formulation and the delivery device. The delivery device and vaccine development whether in liquid form, capsules or powder, can have an affect on the process of...

  • Estado actual de las vacunas contra el Dengue. Perspectivas. Zambrano-Mora, Betzana M. // Revista Biomedica;sep-dic2010, Vol. 21 Issue 3, p197 

    No abstract available.

  • health.  // Access;Feb2008, Vol. 22 Issue 2, p16 

    The article presents research developments related to health in the U.S. The American Academy of Pediatrics and the U.S. Public Health Service agreed that thimerosal should be removed from vaccines. However, subsequent trend surveillance appears to discredit the suspected link. On the other...

  • Immunogenic evaluation and protection of Pasteurella multocida antigens isolated from clinical cases. Cruz, Germán Guadarrama; Lara, Lemuel Leon; Fresán, Maria Uxüa Alonso; de Oca Jiménez, Roberto Montes; Rosas, Pomposo Fernández // Veterinaria México;abr-jun2010, Vol. 41 Issue 2, p101 

    The immunogenic protection response to four P. multocida isolations obtained from clinical cases and a reference strain was studied. Isolations were proven as three different immunogens: complete antigen (Ag), washed Ag and culture supernatant. They were subcutaneously administered in SPF light...

  • Antigenic and genetic characteristics of H5N1 viruses and candidate vaccine viruses developed for potential use in human vaccines, February 2009.  // Weekly Epidemiological Record;2/27/2009, Vol. 84 Issue 9, p72 

    The article provides information on the characteristics of H5N1 viruses and cites the vaccines that are being developed for their prevention. According to the article, these viruses are considered as endemic in other nation and still spreading infections in both human and poultry. Meanwhile, the...

  • Warming diptheria-tetanus vaccines doesn't reduce pain.  // BMJ: British Medical Journal (International Edition);9/6/2003, Vol. 327 Issue 7414, p510 

    Describes the results of a small study made to determine if the warming of diptheria-tetanus vaccine by hand or by machine would reduce the discomfort of the injection. How the study was conducted; Finding of study which suggests that warming failed to reduce the incidence of pain or adverse...

  • Promising SARS Vaccine. Hampton, Tracy // JAMA: Journal of the American Medical Association;8/25/2004, Vol. 292 Issue 8, p916 

    Reports on a promising nasal spray vaccine for SARS. How the experimental vaccine was designed by the National Institute of Allergy and Infectious Diseases; Belief the spray is ready for clinical trials; Evidence that the vaccine strain has been shown safe in children.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics